THE EUROPEAN COMMISSION issued a marketing authorization for lenvatinib (Kisplyx) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib was granted an accelerated assessment by the European Medicines Agency in October 2015. Marketing authorization follows the evaluation of results...
Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).
